Build-Your-Own-Case Study: A Glimpse at Optimal T2D Management: Enhancing Outcomes with GLP-1 RAs - Healio
CE Activity Release Date: October 28, 2022
CE Activity Expiration Date: October 27, 2023
Time to Complete activity: 1.0 hr
DESCRIPTION
Think you fully understand the differences between available glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and their use in the management of Type 2 diabetes (T2D) and comorbidities? Clinicians may under-use GLP-1 RAs or not fully understand the differences between all the available GLP-1 RAs. As a result, unmet needs in T2D management persist, particularly in some ethnic and socioeconomic populations.
Test your knowledge about newest guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2D using GLP-1 RAs by building your own case studies. This will help your patients achieve A1C targets, particularly those with comorbidities including obesity, cardiovascular disease, NAFLD/NASH, transplants, PCOS and more! Additionally, this will help you identify various social determinants of health (SDoH) that may be unrecognizable and help you direct your patients in changing important modifiable behaviors (like sleep, stress, smoking cessation, and alcohol use).
At any point in this Build Your Own Case Study, expert endocrinologists will shed light on current recommendations and evidence for GLP-1 RAs in the management of T2D along with obesity, cardiovascular diseases, and other comorbidities. Our expert faculty will also offer insights on individualizing treatment plans to help your patients reach their goals and reduce comorbidity risks.
Think you have all the tools you need to help your patients? If so, post-test and claiming credit will be a breeze!
TARGET AUDIENCE
This CE Activity is intended for physicians, fellows, NPs, PAs, nurses, and pharmacists who provide care for individuals with T2D.
EDUCATIONAL OBJECTIVES
After completing this CE activity, the participant should be better able to:
- Assess the consequences of suboptimal management of T2D
- Adopt guideline recommended treatment approaches including the appropriate use of GLP-1 RAs
- Evaluate available GLP-1 RAs with respect to mechanism of action, dosing and administration, glycemic and extra-glycemic effects, and adverse events (AEs)
- Optimize the use of GLP-1 RAs to improve patient care and outcomes
AGENDA
Part 1: Unmet needs in T2D and how GLP-1 RAs might address them (expert commentary)
- Challenges in attaining and maintaining A1c goals
- Managing comorbidities (eg, obesity, cardiovascular [CV] risk, chronic kidney disease)
- Guideline discordance; under-utilization of GLP-1 RAs
- GLP-1 RA mechanism of action; the role of GLP in the pathophysiology of T2D; pleiotropic effects on comorbidities (eg, hyperlipidemia, hypertension, and fatty liver) and syndromes (eg, osteoporosis, sleep apnea) that commonly co-occur with diabetes
Part 2: Build your own case (learner interaction interspersed with expert commentary regarding choices)
- Case part 1: Initiating therapy (including shared decision making for treatment selection; use of GLP-1 RAs in patients with a neuroendocrine tumor or pancreatitis)
- Case part 2: Dosing, dosage adjustment, and mode of administration (subcutaneous vs oral; daily vs weekly administration)
- Case part 3: Glycemic and extra-glycemic effects (eg, A1c reduction, weight loss, CV risk reduction)
- Case part 4: Safety concerns; monitoring for and mitigating AEs (eg, gastrointestinal [GI] effects, thyroid C-cell tumors, pancreatitis, diabetic retinopathy, acute kidney injury, chronic kidney disease, heart failure, hypersensitivity reactions, acute gallbladder disease)
Part 3: The role of GLP-1 RAs (expert commentary)
- Place in treatment (eg, for patients who need to minimize hypoglycemia or minimize weight gain/promote weight loss, or are at high risk for or have atherosclerotic CV disease, or for whom metformin is contraindicated); role of GLP-1 RAs vs dipeptidyl peptidase-4 [DPP-4] inhibitors
- Guideline concordance
*The activity concludes with a recap of key points and an evaluation; it includes downloadable resources, eg, practice aids, patient education materials; all approved GLP-1 RAs (ie, dulaglutide, exenatide, liraglutide, lixisenatide, and semaglutide) will be included
ACCREDITATION, SUPPORT AND CREDIT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Endocrine Society and Medical Learning Institute, Inc. (MLI). The Endocrine Society is accredited by the ACCME to provide continuing medical education for physicians.
AMA PRA Category 1 Credits™
The Endocrine Society designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.
Please note that while other accrediting bodies accept AMA PRA Category 1 Credit™, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.
AAPA Credit Designation Statement
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 0.75 contact hour in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-099-H01-P
Type of Activity: Knowledge
INTERPROFESSIONAL CONTINUING EDUCATION (IPCE) STATEMENT
SUPPORT STATEMENT
This activity is supported by an educational grant from Novo Nordisk.
DISCLOSURE & CONFLICT OF INTEREST POLICY
Medical Learning Institute, Inc., and Endocrine Society are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, we require faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to policy. These disclosures will be provided to learners prior to the start of the CE activity.
FACULTY DISCLOSURES
Planner/Presenter
Sean Wharton, MD, PharmD, FRCPC
Medical Director
The Wharton Medical Clinic – Diabetes and Weight Management Centre
Ontario, Canada
Sean Wharton MD, PharmD, FRCPC has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Bausch Health Canada, Eli Lilly, and Novo Nordisk; Research Grant Support for Bausch Health Canada and Novo Nordisk.
Carly E. Kelley, MD, MPH, ECNU
Assistant Professor of Medicine
Endocrinology, Metabolism, and Nutrition
Department of Medicine
Duke University Medical Center
Durham, NC
Carly E. Kelly, MD, MPH, ECNU has no relevant financial relationships with ineligible companies to disclose for this educational activity.
Planner/Presenter
Donna Ryan, MD
Professor Emerita
Pennington Biomedical Research Center
Baton Rouge, LA
Donna Ryan, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Altimmune, Amgen, Calibrate, Epitomee, Gila, Lilly, Novo Nordisk, Roman, Scientific Intake, Wondr Health, Xeno Bioscience, YSOPIA, and Zealand; Speakers' Bureau with Novo Nordisk; Other: Stock Options with Calibrate, Epitomee, Roman, and Scientific Intake. On Data Safety Monitoring Board for Rhythm; Co-chair of steering committee for the SELECT Trial for Novo Nordisk.
Jabiz Behzadpour, DO
Endocrinology Physician
Riverside Healthcare
Kankakee, IL
Jabiz Behzadpour, DO has no relevant financial relationships with ineligible companies to disclose for this educational activity.
All of the relevant financial relationships of individuals for this activity have been mitigated.
PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS
The planners and content/peer reviewers from Medical Learning Institute, Inc., and the Endocrine Society, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are hose of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. Once submitted, the certificate will be automatically generated as a PDF online.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact Mary Vu via email at mvu@mlieducation.org.
For pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
ABOUT THIS ACTIVITY
The Endocrine Society and Medical Learning Institute, Inc. are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc. and the Endocrine Society. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc., Endocrine Society, or any of its partners, providers, and/or supporters.
Copyright © 2022 Medical Learning Institute, Inc | All Rights Reserved
Comments
Post a Comment